Concerns About Compounded Bioidentical Menopausal Hormone Therapy
- 1 May 2022
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (3) , 241-245
Abstract
Following the release of the Women's Health Initiative data, women began to use compounded bioidentical hormone therapy (cBHT) in the misguided belief of greater safety and efficacy than traditional hormone therapy. New guidelines recommend government-approved hormone therapy for symptomatic healthy menopausal women younger than 60 years or within 10 years of menopause at the time of initiation. For women requesting bioidentical hormones, those similar to the hormones present before menopause, there are many government-approved hormone therapies with extensive pharmacokinetic, safety, and efficacy data provided with package inserts delineating efficacy, safety, and potential risks. For women requesting non–Food and Drug Administration–approved (cBHT), these cBHTs lack data on pharmacokinetics, safety, and efficacy and are not provided a label detailing risk. Their use should be restricted to women with allergies or dosing or formulations not available in government-approved therapies. Pellet therapy providing women with supraphysiologic hormone dosing raises even more safety concerns.Keywords
This publication has 38 references indexed in Scilit:
- Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2014
- Use of Compounded Bioidentical Hormone Therapy in Menopausal Women: An Opinion Statement of the Women's Health Practice and Research Network of the American College of Clinical PharmacyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- RETRACTEDObstetrics & Gynecology, 2014
- Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized TrialsJAMA, 2013
- Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical EffectsEndocrine Reviews, 2012
- Compounded bioidentical menopausal hormone therapyFertility and Sterility, 2012
- Misconception and Concerns about Bioidentical Hormones Used for Custom-Compounded Hormone TherapyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Premature menopause or early menopause: Long-term health consequencesMaturitas, 2010
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002